For research use only. Not for therapeutic Use.
JT010（Cat No.:I007460）is an investigational small molecule being developed for the treatment of cancer, particularly solid tumors. It is a selective inhibitor of the protein kinase PI3Kδ (phosphoinositide 3-kinase delta), which plays a crucial role in the regulation of cell growth, survival, and immune responses. Overactivation of the PI3Kδ pathway has been linked to various cancers, including hematologic malignancies and solid tumors. By inhibiting PI3Kδ, JT010 aims to reduce tumor growth and enhance the effectiveness of other cancer therapies. The drug is currently undergoing preclinical and early-stage clinical trials for its safety and therapeutic potential.
| Catalog Number | I007460 |
| CAS Number | 917562-33-5 |
| Synonyms | JT010; JT-010; JT 010.;2-Chloro-N-(4-(4-methoxyphenyl)thiazol-2-yl)-N-(3-methoxypropyl)-acetamide |
| Molecular Formula | C16H19ClN2O3S |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | 2-chloro-N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-N-(3-methoxypropyl)acetamide |
| InChI | InChI=1S/C16H19ClN2O3S/c1-21-9-3-8-19(15(20)10-17)16-18-14(11-23-16)12-4-6-13(22-2)7-5-12/h4-7,11H,3,8-10H2,1-2H3 |
| InChIKey | KZMAWJRXKGLWGS-UHFFFAOYSA-N |
| SMILES | COCCCN(C1=NC(=CS1)C2=CC=C(C=C2)OC)C(=O)CCl |
| Reference | </br>1: Takaya J, Mio K, Shiraishi T, Kurokawa T, Otsuka S, Mori Y, Uesugi M. A Potent and Site-Selective Agonist of TRPA1. J Am Chem Soc. 2015 Dec 23;137(50):15859-64. doi: 10.1021/jacs.5b10162. PubMed PMID: 26630251. |
